Disease Landscape and Forecast Insights

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…

Clarivate Epidemiology’s coverage of restless legs syndrome (RLS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

The osteoporosis therapy market will experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake of Evenity…

Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…

Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…

Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…